Antibiotic Drug Push By Administration Could Include BARDA Incubator
As NIH workshop discusses novel approaches to combatting antibiotic resistance from monoclonal antibodies to synthetic stool transplants and antimicrobial peptides, plans are underway to expand BARDA’s focus beyond biodefense.
You may also be interested in...
Justices acknowledged that the release of the Sackler family from civil liability is a boon for them but appeared averse to rejecting a plan that is supported by the vast majority of victims of the opioid crisis.
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies, the agency’s policy for using background music in direct-to-consumer advertising, and the FDA’s new incoming principal deputy commissioner.
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.